TP53 and lymphoma: Moreover, Wang et al. [19] demonstrate that in mutant-p53 lymphoma cells, ellipticine-mediated reactivation of mutant p53 sensitizes these cells to treatment with further DNA-damaging drugs (i.e., doxorubicin).